» Articles » PMID: 30362022

Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters

Overview
Specialty Oncology
Date 2018 Oct 27
PMID 30362022
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Sarcomas are a heterogeneous group of rare malignancies that arise from mesenchymal cells and can occur anywhere in the body. Herein, the focus will be on one subtype of sarcoma that arises from adipocytic tissue, liposarcoma. Specifically, the review will focus on one type of liposarcoma, myxoid liposarcoma. Given the rarity of this tumor, it is imperative that these patients are treated at a sarcoma center, where a multidisciplinary approach incorporates all the modalities available including clinical trials. As the understanding of the biology of myxoid liposarcomas progresses, more targeted therapies are being developed that will lead to better tolerated treatments and improved survival for patients. In this review, we will be discussing the pathophysiology, clinical presentation, diagnostic workup, and available treatment options including surgery, radiation, chemotherapy, and clinical trials.

Citing Articles

Diagnosis and Treatment of Myxoid Liposarcoma.

Qu G, Zhang C, Tian Z, Yao W Curr Treat Options Oncol. 2024; 25(10):1289-1296.

PMID: 39302575 DOI: 10.1007/s11864-024-01262-9.


Myxoid Liposarcomas of the Thigh: Pre-Operative Presentation, Clinical Outcomes, and Functional Results of Surgical Treatment.

Ipponi E, Bechini E, Cordoni M, Gentili F, Cosseddu F, DArienzo A Healthcare (Basel). 2024; 12(17).

PMID: 39273742 PMC: 11395618. DOI: 10.3390/healthcare12171718.


Mandibular Myxoid Liposarcoma: a Case Study.

Barreras-Espinoza J, Lopez-Uribe P, Leyva-Moraga F, Leyva-Moraga F, Leyva-Moraga E, Ocejo-Gallegos J Indian J Surg Oncol. 2024; 15(Suppl 1):19-21.

PMID: 38545574 PMC: 10963671. DOI: 10.1007/s13193-023-01705-z.


The usefulness of immunohistochemistry for phosphohistone H3 as a prognostic factor in myxoid liposarcoma.

Takazawa A, Yoshimura Y, Okamoto M, Tanaka A, Kito M, Aoki K Sci Rep. 2023; 13(1):4733.

PMID: 36959285 PMC: 10036607. DOI: 10.1038/s41598-023-31896-y.


Case report: Metastatic myxoid liposarcoma arising from the right atrium extends as cardiac tamponade-A rare case of atrial oncology.

Ramamurthy M, Balakrishnan V, Sunny S, Rajkumar A, Sundaram S, Krishnamurthy P Front Cardiovasc Med. 2023; 9:1046436.

PMID: 36776944 PMC: 9909183. DOI: 10.3389/fcvm.2022.1046436.


References
1.
Ray-Coquard I, Ranchere-Vince D, Thiesse P, Ghesquieres H, Biron P, Sunyach M . Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses. Eur J Cancer. 2003; 39(14):2021-5. DOI: 10.1016/s0959-8049(03)00430-1. View

2.
Demetri G, Fletcher C, Mueller E, Sarraf P, NAUJOKS R, Campbell N . Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999; 96(7):3951-6. PMC: 22401. DOI: 10.1073/pnas.96.7.3951. View

3.
Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A . Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19(5):1238-47. DOI: 10.1200/JCO.2001.19.5.1238. View

4.
Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

5.
Smith S, Iwenofu O . NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis. Chin Clin Oncol. 2018; 7(4):44. DOI: 10.21037/cco.2018.08.11. View